Advanced Search
Submit ManuscriptADVANCE ONLINE PUBLICATION
A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant
Zezhong Liu1,† , Jasper Fuk-Woo Chan2,3,4,† , Jie Zhou1,† , Meiyu Wang5,6,† , Qian Wang1 , Guangxu Zhang1 , Wei Xu1 , Kenn Ka-Heng Chik4 , Yilong Zhang7 , Youchun Wang5,6,* , Lu Lu1,* , Kwok-Yung Yuen2,3,4,* , Shibo Jiang1,*
1Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, ChinaDear Editor,
Since the outbreak of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, numerous SARS-CoV-2 variants of concern (VOCs), such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2), have emerged. Recently, the newly identified SARS-CoV-2 VOC, Omicron (B.1.1.529), has rapidly spread in many countries1 and is expected to replace Delta as the dominant variant circulating in the world. Compared to other VOCs, Omicron contains at least 32 mutations in spike (S) protein, including 15 mutations in the receptor-binding domain (RBD), and these mutations are known to confer resistance to neutralizing antibodies (nAbs) and sera of convalescent patients and people who have received COVID-19 vaccines.2,3,4,5 Therefore, vaccines able to induce potent and durable neutralizing antibodies against Omicron and other VOCs are urgently needed.
https://doi.org/10.1038/s41422-022-00631-z